Postoperative Venous Thromboembolism: Improved Coding after New ICD-9-CM Codes but Continuing Opportunities to Improve Care

Banafsheh Sadeghi, MD PhD
Patrick S. Romano, MD MPH
UC Davis Center for Healthcare Policy and Research

AcademyHealth 2012 Annual Research Meeting
June 26, 2012
AHRQ Patient Safety Indicators

- Designed for use with widely available administrative (discharge) data sets
- Reflect aspects of quality of care inside hospitals, focusing on potentially avoidable complications and related iatrogenic events.
- Can be used to help hospitals to identify potential adverse events for further study, and to inform other stakeholders about potential quality problems
- 19 indicators for complications occurring in-hospital; 6 indicators also have area level analogs designed to detect patient safety events on a regional level
- Predictive validity clearly established through correlations with LOS, charges, mortality
## PSI 12 – Postoperative DVT/PE

Early criterion validity findings

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Coding</th>
<th>Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UHC Cohort (n=450)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity</td>
<td>80% (46-100%)</td>
<td>100%</td>
</tr>
<tr>
<td>Specificity</td>
<td>99.5% (99.3-99.6%)</td>
<td>98.6% (98.6-99.2%)</td>
</tr>
<tr>
<td>Positive Predictive Value</td>
<td>72% (67-79%)</td>
<td>44% (37-51%)</td>
</tr>
<tr>
<td>Negative Predictive Value</td>
<td>99.6% (98.9-100%)</td>
<td>100%</td>
</tr>
<tr>
<td><strong>VA Cohort (n=112)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive Predictive Value</td>
<td></td>
<td>43% (34-53%)</td>
</tr>
<tr>
<td><strong>AHRQ Cohort (n=121)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive Predictive Value</td>
<td>84% (72-95%)</td>
<td>47% (42-52%)</td>
</tr>
</tbody>
</table>

University HealthSystem Consortium cohort includes 505 flagged, randomly sampled surgical cases from 33 volunteer hospitals in 21 states; 450 cases were fully abstracted and submitted to UHC.
Background

- Previous validation studies showed poor predictive value due to:
  - High prevalence of DVT present on admission or chronic DVT
  - Use of nonspecific codes for upper extremity, thoracic, and superficial venous thromboses
  - Preoperative but post-admission DVT in acutely ill patients

- POA reporting introduced for all Medicare claims and many statewide data programs

- New ICD-9-CM codes implemented in FY 2010 update to capture superficial, upper extremity, and chronic venous thromboses
Previous validation studies showed poor predictive value due to:

- High prevalence of DVT present on admission or chronic DVT
- Use of nonspecific codes for upper extremity, thoracic, and superficial venous thromboses
- Preoperative but post-admission DVT in acutely ill patients

POA reporting introduced for all Medicare claims and many statewide data programs

New ICD-9-CM codes implemented in FY 2010 update to capture superficial, upper extremity, and chronic venous thromboses

Are the problems fixable or is PSI 12 irredeemable?
453.4 Acute venous embolism and thrombosis of deep vessels of lower extremity
   453.40 Acute venous embolism and thrombosis of unspecified deep vessels of lower extremity
   Deep vein thrombosis NOS
   453.41 Acute venous embolism and thrombosis of deep vessels of proximal lower extremity
   Femoral, Iliac, Popliteal, Thigh, Upper leg NOS
   453.42 Acute venous embolism and thrombosis of deep vessels of distal lower extremity
   Calf, Lower leg NOS, Peroneal, Tibial

453.5 Chronic venous embolism and thrombosis of deep vessels of lower extremity
   Excludes: personal history of venous thrombosis and embolism (V12.51)
   453.50 Chronic venous embolism and thrombosis of unspecified deep vessels of lower extremity
   453.51 Chronic venous embolism and thrombosis of deep vessels of proximal lower extremity
   453.52 Chronic venous embolism and thrombosis of deep vessels of distal lower extremity

453.6 Venous embolism and thrombosis of superficial vessels of lower extremity

453.7 Chronic venous embolism and thrombosis of other specified vessels
   Excludes: personal history of venous thrombosis and embolism (V12.51)
   453.71 Chronic venous embolism and thrombosis of superficial veins of upper extremity
   453.72 Chronic venous embolism and thrombosis of deep veins of upper extremity
   453.73 Chronic venous embolism and thrombosis of upper extremity, unspecified
   453.74 Chronic venous embolism and thrombosis of axillary veins
   453.75 Chronic venous embolism and thrombosis of subclavian veins
   453.76 Chronic venous embolism and thrombosis of internal jugular veins
   453.77 Chronic venous embolism and thrombosis of other thoracic veins
   453.79 Chronic venous embolism and thrombosis of other specified veins

453.8 Acute venous embolism and thrombosis of other specified veins
   Excludes: cerebral, coronary, intracranial sinus, nonpyogenic, mesenteric, portal, precerebral, pulmonary
   453.81 Acute venous embolism and thrombosis of superficial veins of upper extremity
   453.82 Acute venous embolism and thrombosis of deep veins of upper extremity
   453.83 Acute venous embolism and thrombosis of upper extremity, unspecified
   453.84 Acute venous embolism and thrombosis of axillary veins
   453.85 Acute venous embolism and thrombosis of subclavian veins
   453.86 Acute venous embolism and thrombosis of internal jugular veins
   453.87 Acute venous embolism and thrombosis of other thoracic veins
   453.89 Acute venous embolism and thrombosis of other specified veins

453.9 Of unspecified site (embolism of vein, thrombosis (vein))
Methods

Two parallel studies were conducted to update previous PPV estimates for PSI 12 and to identify actionable opportunities to improve care:

- 7 volunteer hospitals recruited through AHRQ QI listserve, including flagged cases only
- 15 academic health systems recruited through UHC, including both flagged and unflagged cases with TKA surgery

AHRQ PSI 12 Version 4.1 software was applied to eligible cases from participating hospitals, using “present on admission” (POA) flags.

- Hospital’s own data (AHRQ) or Clinical Database (UHC)
Methods

- Flagged cases were reviewed by trained QI nurses at each hospital, using detailed chart abstraction tool and guidelines.

- Detailed review of discrepant cases to identify possible reasons for the discrepancy:
  - Present on admission (note one hospital did not apply denominator exclusions)
  - Location of thrombosis (upper extremity and superficial thromboses are clinical FPs)
  - Chronic vs. acute embolism (based on radiographic criteria)

- Records from volunteer hospitals in AHRQ study were sampled in sequential reverse order from 6/30/2010 back to 10/1/2009, up to N=30
Case Control Study

Cases (up to 20):
- Uni-TKA or Bilat-TKA
- Oct 2008 to Mar 2010
- >40 yrs
- PSI-12 code for VTE within 90 days

Controls (up to 40):
- Uni-TKA or Bilat-TKA
- Oct 2008 to Mar 2010
- >40 yrs
- NO PSI-12 code for VTE within 90 days

- No TKA or THA within 90 days prior
- No VTE as principal ICD-9-CM diagnosis
- No VTE as POA
- No pregnancy, childbirth, or puerperium
Analysis

- TP / (TP + FP) = PPV
- Classified FDA-approved pharmacologic prophylaxis as receipt of the recommended dose at the recommended starting time (per package insert) before or after surgery, and continued until at least the day of discharge.
- Patients who were diagnosed with VTE on the day of surgery or the day after surgery were not included in the case control analysis.
- Other risk factors assessed included age, obesity (BMI), type of TKA, race/ethnicity, date of ambulation, personal or family history of VTE, and comorbid conditions.
- Analysis adjusted for conditional stratified sampling of controls without VTE.
Findings: 7 volunteer hospitals

- From a total of 171 audited charts, 15 cases were excluded post hoc (because hospital did not properly apply POA)
- 30 cases were False Positive:
  - 15 cases were POA
  - 8 cases with upper extremity VT
  - 1 case with SVC (central VT)
  - 3 cases with superficial VT
  - 3 cases were chronic
- Overall PPV = 81%
Findings: AMCs with TKA patients
PSI-12 flagged cases

126 VTE flagged by PSI 12 (+4 Readmission)

- 125 cases True Positive postop lower ext DVT or PE
- 1 case clinical False Positive (superficial) saphenous Vein

Positive Predictive Value
= TP / (TP + FP)
= 125 / (125 + 1)
= 0.992
Findings: AMCs with TKA patients
PSI-12 unflagged controls

Chart Abstraction

463 Not flagged as VTE by PSI 12

- 5 cases had VTE per UHC abstract
- 458 cases had no VTE (TN)

3 cases False Negative
2 cases superficial or upper extremity thromboses

Negative Predictive Value
= TN / (FN + TN)
= 458 / (458+3) = 0.993
Multivariable Analysis

Multivariate Adjusted Odds Ratios and 95% Confidence Intervals

- Outcome: Any VTE Event Diagnosed Day 2 of Surgery or Later
- Excluded One Hospital That Screened TKA Patients Routinely For VTE

<table>
<thead>
<tr>
<th>Predictive Factor</th>
<th>Odds Ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.02 (0.99 – 1.05)</td>
<td>0.20</td>
</tr>
<tr>
<td>Gender (ref: male)</td>
<td>1.7 (0.9 – 2.9)</td>
<td>0.90</td>
</tr>
<tr>
<td>Ambulation (ref: no ambulation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taking steps day 1 or 2</td>
<td>0.3 (0.1 – 0.9)</td>
<td>0.005</td>
</tr>
<tr>
<td>Taking steps after day 2</td>
<td>0.7 (0.2 – 2.1)</td>
<td>0.56</td>
</tr>
<tr>
<td>Type of TKA (ref: unilateral TKA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilateral TKR</td>
<td>4.2 (1.9 – 9.1)</td>
<td>0.004</td>
</tr>
<tr>
<td>Recommended pharmacologic prophylaxis (ref: only mechanical)</td>
<td>0.5 (0.3 – 0.8)</td>
<td>0.01</td>
</tr>
<tr>
<td>BMI ≥ 35 (ref: BMI &lt; 35)</td>
<td>0.9 (0.5 – 1.6)</td>
<td>0.66</td>
</tr>
</tbody>
</table>
Interaction terms

None of the interactions between obesity, type of prophylaxis, type of surgery or time to ambulation were significant (but analysis was underpowered)

- There was no significant difference in the effect of LMWH among extremely obese versus non/less obese patients
- There was no significant difference in the effect of use of any medical prophylaxis among extremely obese versus non/less obese patients
Summary

- PPV was substantially higher than previously reported (81% versus 43-47%) in PSI-12 flagged cases from volunteer hospitals.
- PPV was especially high in a subset of surgical cases with low prior probability of VTE (99.2%).
- Continuing evidence of high sensitivity (99.3% NPV among high-risk patients).
- In the setting of 100% TJC SCIP compliance:
  - VTE after TKA was associated with not receiving pharmacologic thromboprophylaxis at FDA-approved doses and initiation schedule.
  - Bilateral TKA was associated with higher odds of VTE.
  - Early mobilization was associated with lower odds of VTE.
  - Medical prophylaxis was as effective in morbidly obese as in less obese patients.
Limitations and implications

- Volunteer hospitals in AHRQ sample
- Academic medical centers in UHC sample
- UHC sample limited to TKA (high-risk) patients
- Hospital abstractors may have covered up false negative (unreported) cases
- ICD-9-CM changes and associated coder training can substantially improve criterion validity of PSIs, in the right circumstances
- Actionable opportunities to improve care to prevent VTE persist despite 100% compliance with existing TJC process measures
- Value of outcome measure confirmed
Acknowledgments and references

- Participating hospitals and systems: Advocate Health Care, Barnes Jewish Hospital, Harborview Med Ctr, Nebraska Medical Ctr, Stanford Hospital, UC Davis Medical Ctr, Vassar Brothers Med Ctr.
- AHRQ Quality Indicators project team: Mamatha Pancholi, John Bott
- Battelle validation support: Jeffrey Geppert, Jaime Liesmann
- UC Davis: Pat Zrelak, Ruth Baron, Richard White, Garth Utter
Questions and Discussion